Table 2.

Univariate Analysis of the Associations Between Prognostic Value and Disease-Free and Overall Survival Rates in Patients with Early-Stage Cervical Adenocarcinoma

Variable	Disease-Free Survival			Overall Survival
	HR	95% CI	P	HR	95% CI	P
Patient age (years)	2.042	0.846–4.927	0.112	1.694	0.643–4.459	0.286
FIGO stage	6.300	2.551–15.558	6.60E−5*	4.223	1.471–12.121	0.007*
BMI	1.944	0.789–4.788	0.148	2.001	0.757–5.288	0.162
Menopause	1.564	0.521–4.695	0.425	1.142	0.327–3.992	0.836
Differentiation	5.980	2.442–14.643	9.10E−5*	5.181	1.945–13.803	0.001*
Tumor size (cm)	1.053	0.308–3.597	0.935	0.848	0.194–3.713	0.827
Myometrial invasion	7.627	2.908–20.008	3.60E−5*	5.916	2.182–16.041	4.78E−4*
Vaginal wall extension	3.397	0.989–11.666	0.052	3.284	0.733–14.713	0.120
Parametrial extension	9.634	2.204–42.112	0.003*	11.434	2.546–51.343	0.001*
Endometrial extension	6.278	2.268–17.380	4.06E−4*	3.931	1.210–12.767	0.023*
LVSI	0.747	0.100–5.598	0.776	1.097	0.143–8.395	0.929
LNM	1.504	0.438–5.169	0.517	1.958	0.560–6.847	0.293
Surgical margin	0.049	0.000–6.309 E+8	0.800	0.049	0.000–1.934E+14	0.869
Histological type	0.524	0.121–2.257	0.385	0.624	0.142–2.735	0.532
SCC	1.102	0.142–8.540	0.926	1.372	0.171–11.004	0.766
CA125	3.358	1.281–8.803	0.014*	2.649	0.918–7.644	0.071
AFP	0.049	0.000–5.437E+11	0.844	0.049	0.000–9.850E+12	0.858
CEA	2.972	1.124–7.860	0.028*	3.050	1.105–8.416	0.031*
CA153	0.049	0.000–6.855 E+8	0.800	0.049	0.000–2.287E+11	0.840
CA199	4.504	0.502–40.366	0.179	8.572	0.775–94.778	0.080
Combination of CA125 and CEA	5.492	1.803–16.729	0.003*	5.141	1.623–16.287	0.005*

Note: *Significant differences (P < 0.05) of the associations between prognostic value and disease-free and overall survival rates in patients with early-stage cervical adenocarcinoma.

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index; LVSI, lymph vascular space invasion; LNM, lymph node metastasis; HR, hazard ratio; 95% CI, 95% confidence interval.